Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 1796 results found since Jan 2013.

A population based study of the epidemiology of Herpes Zoster and its complications
Conclusions: Extrapolating to the entire Israeli population, we estimate over 24,000 new cases of HZ and 1250 new cases of PHN each year. Cost-effectiveness analysis should be performed to determine the threshold age for vaccination against HZ.
Source: Journal of Infection - July 18, 2013 Category: Infectious Diseases Authors: Dahlia Weitzman, Oren Shavit, Michal Stein, Raanan Cohen, Gabriel Chodick, Varda Shalev Tags: Viruses and Viral Diseases Source Type: research

Herpes Zoster Linked Again to Increased Stroke, MIHerpes Zoster Linked Again to Increased Stroke, MI
The vaccine that reduces herpes zoster might also cut risks for vascular events, including stroke, transient ischemic attack, and myocardial infarction, researchers speculate. Medscape Medical News
Source: Medscape Cardiology Headlines - January 2, 2014 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: Herpes zoster vaccine is effective in preventing herpes zoster disease. Although vaccine benefits are larger in the younger age group (60 to 69 years), this is also the age group with more adverse events. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity. PMID: 25055074 [PubMed - as supplied by publisher]
Source: Sao Paulo Medical Journal - July 24, 2014 Category: Journals (General) Authors: Gagliardi AM, Silva BN, Torloni MR, Soares BG Tags: Sao Paulo Med J Source Type: research

Systematic review of incidence and complications of herpes zoster: towards a global perspective
Conclusions HZ is a significant global health burden that is expected to increase as the population ages. Future research with rigorous methods is important.
Source: BMJ Open - June 10, 2014 Category: Journals (General) Authors: Kawai, K., Gebremeskel, B. G., Acosta, C. J. Tags: Open access, Epidemiology, Global health, Infectious diseases Research Source Type: research

Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
Conclusions: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination.
Source: BMC Public Health - June 5, 2015 Category: Consumer Health News Authors: Oliver DammBernhard UltschJohannes HornRafael MikolajczykWolfgang GreinerOle Wichmann Source Type: research

Live attenuated herpes zoster vaccine for HIV‐infected adults
ConclusionsIt is recommended that LAHZV be administered to HIV‐infected adults with a CD4 count above 200 cells/μL, the same CD4 threshold used for other live attenuated viral vaccines.
Source: HIV Medicine - August 29, 2015 Category: Infectious Diseases Authors: SD Shafran Tags: Viewpoints on HIV Research Source Type: research

Vaccines for preventing herpes zoster in older adults.
CONCLUSIONS: Herpes zoster vaccine is effective in preventing herpes zoster disease and this protection can last three years. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity.There are studies of a new vaccine (with a VZV glycoproteic fraction plus adjuvant), which is currently not yet available for clinical use. PMID: 26937872 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 3, 2016 Category: Journals (General) Authors: Gagliardi AM, Andriolo BN, Torloni MR, Soares BG Tags: Cochrane Database Syst Rev Source Type: research

Herpes zoster and the search for an effective vaccine
This article reviews VZV pathogenesis, host responses and current vaccines available to prevent herpes zoster. This article is protected by copyright. All rights reserved.
Source: Clinical and Experimental Immunology - April 30, 2016 Category: Allergy & Immunology Authors: Nicole Arnold, Ilhem Messaoudi Tags: Review Source Type: research

Why the Chicken Pox Vaccine Makes NO Sense
The chicken pox vaccine, formally known as the varicella vaccination, was added to the recommended childhood vaccination schedule in 1995. Prior to this vaccine’s creation, it was a common practice for families to expose children to others who had the chicken pox. The disease was considered a normal part of childhood and it was widely known that chicken pox in childhood posed little to no risk of serious harm. Risks associated with chicken pox are more common in adults and those with compromised immune systems. My Experience With The Chicken Pox Illness And Vaccination I clearly remember exposing my middle child to my ol...
Source: vactruth.com - May 26, 2016 Category: Allergy & Immunology Authors: Michelle Goldstein Tags: Logical Michelle Goldstein Recent Articles chicken pox shingles truth about vaccines Varicella vaccine Source Type: blogs

Endothelial Dysfunction May Play a Key Role in Keloid and Hypertrophic Scar Pathogenesis -Keloids and Hypertrophic Scars May Be Vascular Disorders-
Keloids and hypertrophic scars are fibroproliferative disorders (FPDs) of the skin that result from abnormal healing of injured or irritated skin. They can be called pathological or inflammatory scars. Common causes are trauma, burn, surgery, vaccination, skin piercing, folliculitis, acne, and herpes zoster infection. The pathogenesis of these scars clearly involves local conditions such as delayed wound healing, wound depth, and the tension of the skin around the scars. Scar severity is also shaped by interactions between these local factors and genetic and systemic factors such as hypertension and sex hormones.
Source: Medical Hypotheses - September 26, 2016 Category: Biomedical Science Authors: Rei Ogawa, Satoshi Akaishi Source Type: research

Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis – Keloids and hypertrophic scars may be vascular disorders
Keloids and hypertrophic scars are fibroproliferative disorders (FPDs) of the skin that result from abnormal healing of injured or irritated skin. They can be called pathological or inflammatory scars. Common causes are trauma, burn, surgery, vaccination, skin piercing, folliculitis, acne, and herpes zoster infection. The pathogenesis of these scars clearly involves local conditions such as delayed wound healing, wound depth, and the tension of the skin around the scars. Scar severity is also shaped by interactions between these local factors and genetic and systemic factors such as hypertension and sex hormones.
Source: Medical Hypotheses - September 26, 2016 Category: Biomedical Science Authors: Rei Ogawa, Satoshi Akaishi Source Type: research

Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
CONCLUSIONS: Although live vaccinations were safe and sufficiently immunogenic in most studies, some serious reactions and vaccine-related infections were reported in immunosuppressed IMID and SOT patients. Apart from mild vaccine-related infections MMR and VV vaccines were safe when administered less than two years after BMT. IMPLICATIONS OF KEY FINDINGS: Until further data are available, live vaccinations under most immunosuppressive treatments should only be administered after a careful risk benefit assessment of medications and dosages. FUNDING: None. PMID: 28162821 [PubMed - as supplied by publisher]
Source: Vaccine - February 1, 2017 Category: Allergy & Immunology Authors: Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S Tags: Vaccine Source Type: research

Improving adult immunization equity: Where do the published research literature and existing resources lead?
Abstract Evidence suggests that disparities in adult immunization (AI) rates are growing. Providers need adequate patient resources and information about successful interventions to help them engage in effective practices to reduce AI disparities. The primary purposes of this paper were to review and summarize the evidence base regarding interventions to reduce AI disparities and to scan for relevant resources that could support providers in their AI efforts to specifically target disparities. First, building on a literature review conducted by the U.S. Centers for Disease Control and Prevention, we searched the p...
Source: Vaccine - April 25, 2017 Category: Allergy & Immunology Authors: Prins W, Butcher E, Hall LL, Puckrein G, Rosof B Tags: Vaccine Source Type: research

Cutaneous varicella zoster virus infection following zoster vaccination: report of post-vaccination herpes zoster skin infection and literature review of zoster vaccination efficacy and guidelines. Stiff, Katherine M; Cohen, Philip R
Background Herpes zoster vaccine is currently recommended in the United States for immune competent individuals ≥60 years. The efficacy of the herpes zoster vaccine decreases with age and with time following vaccination. Purpose An elderly man with herpes zoster following vaccination is described. The guidelines for vaccination and issues regarding re-vaccination are reviewed. Methods: Pub Med was used to search the following terms: efficacy, elderly, herpes zoster, herpes zoster incidence, herpes zoster recurrence, and vaccination. The papers and relevant citations were reviewed. The clinical features of a patie...
Source: Dermatology Online Journal - January 1, 2017 Category: Dermatology Source Type: research

Cutaneous varicella zoster virus infection following zoster vaccination: report of post-vaccination herpes zoster skin infection and literature review of zoster vaccination efficacy and guidelines.
ConclusionsHerpes zoster vaccine decreases in efficacy with both age and number of years following vaccination. Therefore, booster shots or revaccination in the older population may be of benefit. PMID: 28633742 [PubMed - in process]
Source: Dermatol Online J - June 15, 2017 Category: Dermatology Authors: Stiff KM, Cohen PR Tags: Dermatol Online J Source Type: research